Combi-TED: a new trial testing Tedopi
Tedopi®
chemo-immunotherapy
docetaxel
nivolumab
non-small-cell lung cancer
overall survival
phase II trial
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
medline:
28
3
2023
pubmed:
23
3
2023
entrez:
22
3
2023
Statut:
ppublish
Résumé
Despite the positive results obtained by first-line chemoimmunotherapy in patients with metastatic non-small-cell lung cancer (NSCLC), only a few second-line options are available after disease progression. Combi-TED is a phase II international study that will assess the efficacy of Tedopi Patients with lung cancer that has spread to other parts of the body are usually treated with a combination of chemotherapy and drugs that stimulate the immune system to kill cancer cells, which is referred to as immunotherapy. If after receiving these drugs the cancer still gets worse, patients have only a few treatment options left and are usually treated with chemotherapy only. Researchers will study if a new medicine called Tedopi
Autres résumés
Type: plain-language-summary
(eng)
Patients with lung cancer that has spread to other parts of the body are usually treated with a combination of chemotherapy and drugs that stimulate the immune system to kill cancer cells, which is referred to as immunotherapy. If after receiving these drugs the cancer still gets worse, patients have only a few treatment options left and are usually treated with chemotherapy only. Researchers will study if a new medicine called Tedopi
Identifiants
pubmed: 36946237
doi: 10.2217/fon-2022-0913
doi:
Substances chimiques
Docetaxel
15H5577CQD
Nivolumab
31YO63LBSN
Banques de données
ClinicalTrials.gov
['NCT04884282']
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4457-4464Subventions
Organisme : Fondazione Ricerca Traslazionale (FoRT)